论文部分内容阅读
目的 :观察抗CD2 0单抗联合环磷酰胺、长春新碱、阿霉素及泼尼松治疗初诊的弥漫性大B细胞淋巴瘤 (DLBL)的临床疗效。方法 :2 0 0 2 0 4 - 2 0 0 3 0 2 ,5 2例病人进入本研究。化疗采用标准的CHOP方案 :环磷酰胺 6 0 0mg/m2 (第 1天 ) ,长春新碱 1.4mg/m2 (第 1天 ) ,阿霉素 2 5mg/m2 (第 1天 )和泼尼松 6 0mg/d(第 1～ 5天 ) ,每 3周 1个疗程 ,共 6个疗程。利妥昔单抗静脉滴注剂量为 375mg/m2 ,每周或每 3周输注 1次 ,连续 4次或 6次。结果 :在 5 0例患者中 ,6 0 %获得完全反应 (CR) ,总有效率 (OR)为 10 0 %。 5 0例患者共随访了 2～ 30周 ,患者 16周的疾病无进展生存 (PFS)率为 87.3%。主要不良反应为输注相关的不良反应 (32 % )和化疗相关的血液学毒副反应 (2 0 % )。结论 :利妥昔单抗联合CHOP方案可有效用于治疗新诊断的弥漫性大B细胞性淋巴瘤具有较高的缓解率 ,不良反应较少。
Objective: To observe the clinical efficacy of anti-CD20 monoclonal antibody combined with cyclophosphamide, vincristine, doxorubicin and prednisone in the treatment of newly diagnosed diffuse large B-cell lymphoma (DLBL). Methods: Two hundred twenty two patients entered the study. Chemotherapy was performed using standard CHOP regimen: cyclophosphamide at 600 mg / m2 on day 1, vincristine at 1.4 mg / m2 on day 1, adriamycin 25 mg / m2 on day 1 and prednisone 6 0mg / d (days 1 to 5), a course of treatment every 3 weeks, a total of 6 courses. Rituximab intravenous infusion dose of 375mg / m2, weekly or infusion once every 3 weeks, 4 times or 6 consecutive times. Results: Of the 50 patients, 60% achieved complete response (CR) with a total effective rate (OR) of 10%. Fifty patients were followed up for 2 to 30 weeks, with a 16-week disease-free survival (PFS) rate of 87.3%. The main adverse reactions were infusion-related adverse events (32%) and chemotherapy-related hematologic toxicities (20%). Conclusion: Rituximab combined with CHOP regimen can be effectively used to treat newly diagnosed diffuse large B-cell lymphoma with high remission rate with fewer adverse reactions.